Tirzepatide, marketed as Mounjaro, targets two hormones: GLP-1 and gastric inhibitory polypeptide (GIP)
These drugs that are FDA-approved for the treatment of diabetes have emerged as a promising new tool in the fight against obesity
While formal evidence remains in development, the mechanistic rationale is compelling: sustained, gentle GLP-1 receptor activation may favorably influence glucose metabolism, cardiovascular integrity, and neuroprotection, all while maintaining tolerability and adherence
Like the injection, they'll be prescription-only once available in the UK
Ratio Improvement: Despite absolute muscle loss, the STEP 1 trial showed that the proportion of lean mass relative to total body weight actually increased
Glucagon-Like Peptide-1 Agonism : Retatrutide incorporates specific alpha-aminobutyric acid substitutions at critical nodes along its amino acid chain